<DOC>
	<DOCNO>NCT00546923</DOCNO>
	<brief_summary>To examine efficacy safety venlafaxine XR treatment physical emotional symptom patient operationally-defined diagnosis multisomatoform disorder ( MSD ) .</brief_summary>
	<brief_title>Study Evaluating Venlafaxine Extended-Release Depressed Anxious Patients</brief_title>
	<detailed_description>The purpose study examine efficacy safety venlafaxine XR treatment physical emotional symptom patient operationally-defined diagnosis MSD . Primary efficacy evaluate use PHQ-15 scale , secondary efficacy evaluate use HAM-D17 , HAM-A , CGI , MQOL-PS , VAS SF-36 evaluation scale . Assessment scale questionnaire administer specified clinical visit screen Week 12 ( discontinuation ) .</detailed_description>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<criteria>Â· Subjects must least 18 year age meet DSMIV diagnostic criterion major depressive disorder , generalize anxiety disorder , and/ social anxiety disorder , meet clinical criterion MSD , total score great equal 14 HAMD17 total score great equal 12 HAMA screen 25 % decrease total HAMD17 score total HAMA score screen randomization . history inability tolerate failure respond great equal 2 antidepressant sufficient dose duration administration treatment symptom present current illness ; current past history mania , bipolar disorder , schizophrenia , psychotic disorder ; history seizure disorder childhood febrile seizure ; presence serious clinically unstable medical illness psychiatric condition would compromise participation study ; previous intolerance hypersensitivity venlafaxine venlafaxine XR nonresponse previous adequate trial drug , use nonpsychopharmacologic drug psychotropic effect within 7 day study randomization ; Use MAOI fluoxetine within 30 day screen ; Use ECT within 3 month screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
</DOC>